In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

TRIANA Study: Primary angioplasty versus fibrinolysis in the very elderly

Hot Line II

Acute Coronary Syndromes (ACS)

Read the press release

Presenter | see Discussant report

Hector Bueno, FESC (Spain)

Presentation webcast

Presentation slides

List of Authors:
Héctor Bueno, Joaquín J. Alonso, Amadeo Betriu, Angel Cequier, Eulogio J. Garcia, Magda Heras, Jose L. Lopez-Sendon, Carlos Macaya, Rosana Hernandez-Antolin, on behalf of the TRIANA investigators, Spanish Society of Cardiology, Madrid, Spain

Abstract : 

Primary angioplasty (PCI) is currently considered the preferred reperfusion therapy for STEMI. However, data on clinical outcomes comparing primary PCI vs. fibrinolysis in very old patients are scarce.

The TRIANA study ( # NCT00257309) is a Spanish multicenter randomized trial comparing primary PCI versus a conservative strategy consisting in fibrinolysis (weight-adjusted TNK+UFH) and rescue PCI. Included patients were 75 years of age or older presenting within 6 hours after STEMI. Patients with accepted contraindications for fibrinolysis and those with any previous cerebrovascular event, cardiogenic shock or blood pressure >180/110 mmHg at any time during the event were excluded. The primary endpoint was the composite of all-cause death, recurrent myocardial infarction, or disabling stroke at 30 days. Secondary endpoints were recurrent ischemia leading to revascularization, and major bleeding. Events were adjudicated by an “ad hoc” committee blinded to the study treatments.

The trial was prematurely stopped due to slow recruitment, after enrolling 266 out of the 560 planned patients. Mean age was 81 years and 56% men. The two treatment groups were well balanced with regard to demographic characteristics and risk factors.

Outcomes at 30 days were as follows. After one-year follow-up, results tended to equate.


In spite of the sample size limitation, this trial shows a trend towards a lower mortality, reinfarction and disabling stroke in elderly patients undergoing primary PCI compared with fibrinolysis. In addition, recurrent ischemia is dramatically reduced by primary PCI. Therefore, this approach might also be recommended for the oldest patients presenting with STEMI.

Discussant | see Presenter abstract

Dariusz Dudek, FESC (Poland)

Presentation webcast

Presentation slides




Primary angioplasty versus fibrinolysis in the very elderly. The TRIANA Study

Notes to editor

This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.